Viewing Study NCT03288012


Ignite Creation Date: 2025-12-26 @ 10:46 PM
Ignite Modification Date: 2025-12-26 @ 10:46 PM
Study NCT ID: NCT03288012
Status: UNKNOWN
Last Update Posted: 2019-07-19
First Post: 2017-09-13
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Sickle Cell Disease: Targeting Alloantibody Formation Reduction; Risk Factors, and Genetics
Sponsor: Sanquin Research & Blood Bank Divisions
Organization:

Study Overview

Official Title: Sickle Cell Disease: Targeting Alloantibody Formation Reduction; Risk Factors, and Genetics
Status: UNKNOWN
Status Verified Date: 2018-08
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: STARRING
Brief Summary: The focus of the study is the pathophysiological mechanism of allo-antibody formation after red blood cell transfusion in sickle cell disease patients.
Detailed Description: The main objectives of this study are to study the role of the innate and adaptive immune response in allo-antibody formation and furthermore to identify the genetic and time dependent clinical risk factors on alloimmunization in SCD patients.

Subjects without allo-antibodies, receiving a red blood cell transfusion, will be included in this study. At 5 time points blood will be drawn from these subjects. (T0: Before transfusion, T1: 1 day after transfusion, T2: 1 week after transfusion, T3: 4 weeks after transfusion, T4: 6 months after transfusion).

At each time point specific markers of the immune system will be measured.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: